Shares of Zosano Pharma Corp (NASDAQ:ZSAN) traded down 9.2% during trading on Tuesday . The company traded as low as $0.54 and last traded at $0.59. 779,388 shares were traded during trading, a decline of 47% from the average session volume of 1,464,548 shares. The stock had previously closed at $0.65.
Separately, ValuEngine raised Zosano Pharma from a “strong sell” rating to a “sell” rating in a report on Friday, September 1st.
The firm has a market capitalization of $23.27 and a price-to-earnings ratio of -0.50.
Zosano Pharma (NASDAQ:ZSAN) last released its earnings results on Thursday, November 9th. The biotechnology company reported ($0.20) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.15) by ($0.05). sell-side analysts forecast that Zosano Pharma Corp will post -0.9 EPS for the current fiscal year.
In other Zosano Pharma news, Director Kenneth Greathouse bought 95,000 shares of Zosano Pharma stock in a transaction dated Friday, December 1st. The stock was bought at an average cost of $0.62 per share, with a total value of $58,900.00. Following the completion of the acquisition, the director now directly owns 95,000 shares in the company, valued at approximately $58,900. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Over the last ninety days, insiders bought 200,000 shares of company stock valued at $123,450. 2.95% of the stock is currently owned by corporate insiders.
An institutional investor recently raised its position in Zosano Pharma stock. Vanguard Group Inc. boosted its position in Zosano Pharma Corp (NASDAQ:ZSAN) by 20.8% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 1,217,323 shares of the biotechnology company’s stock after purchasing an additional 209,251 shares during the period. Vanguard Group Inc. owned about 3.11% of Zosano Pharma worth $1,716,000 as of its most recent SEC filing. Institutional investors own 19.41% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: “Zosano Pharma (ZSAN) Trading Down 9.2%” was first posted by Transcript Daily and is owned by of Transcript Daily. If you are viewing this article on another website, it was copied illegally and reposted in violation of United States and international copyright laws. The correct version of this article can be accessed at https://transcriptdaily.com/2017/12/27/zosano-pharma-zsan-trading-down-9-2.html.
Zosano Pharma Company Profile
Zosano Pharma Corporation is a clinical-stage specialty pharmaceutical company. The Company has developed a transdermal microneedle patch system to deliver its formulations of existing drugs through the skin for the treatment of a range of indications. Its microneedle patch system offers consistent drug delivery and improved ease of use and room-temperature stability.
Receive News & Ratings for Zosano Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zosano Pharma and related companies with MarketBeat.com's FREE daily email newsletter.